By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    Improved Digestion
    Five tips to boost digestion and metabolism
    November 4, 2022
    health insurance for young adults
    Benefits of Buying Health Insurance for Your Adults
    January 12, 2023
    broken hip recovery
    4 Ways to Recover from a Broken Hip
    March 14, 2023
    Latest News
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
    Chewing Matters More Than You Think: Why Proper Chewing Supports Better Health
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Personalized Prevention, Part I
    February 23, 2012
    Everything We Are Doing in Health Policy May Be Completely Wrong
    July 26, 2011
    Personalized Prevention, Part II – The Psychology of Engagement
    March 15, 2012
    Latest News
    Streamlining Healthcare Operations: How Our Consultants Drive Efficiency and Overall Improvement
    June 11, 2025
    Building Smarter Care Teams: Aligning Roles, Structure, and Clinical Expertise
    May 18, 2025
    The Critical Role of Healthcare in Personal Injury Recovery: A Comprehensive Guide for Victims
    May 14, 2025
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Immunotherapy Trains the Immune System to Attack Cancer Cells
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > News > Immunotherapy Trains the Immune System to Attack Cancer Cells
NewsSpecialties

Immunotherapy Trains the Immune System to Attack Cancer Cells

HerinaAyot
Last updated: June 6, 2012 2:32 pm
HerinaAyot
Share
4 Min Read
SHARE

Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness. Treating infectious disease using the body’s own defenses operates under the premise that the body is able to retain memory to guard against disease.

Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness. Treating infectious disease using the body’s own defenses operates under the premise that the body is able to retain memory to guard against disease. Cancer immunotherapy operates under a similar premise.

The Wall Street Journal recently published an article highlighting two drugs Bristol-Myers Squibb presented at the American Society of Clinical Oncology (ASCO) last weekend in Chicago.  The presentation came on the heels of last year’s regulatory approval for Yervoy, a drug that employs the immune system to treat advanced Melanoma. Researchers were impressed with its ability to provide long term survival in more than 20% of patients.  The stock peaked at just over $34.00 at today’s open, but has since declined.

Also mentioned in the WSJ were pharma giants, Roche, Merck, and GlaxoSmithKline as pursuers of immunotherapies. But neglected were smaller emerging companies with big ideas in the same field.

More Read

6 Supplements That Can Help Improve Your Health
Antibiotic Resistant Bacteria Are A Major Threat – Preventing Transmission is Critical
Urinalysis Via Mobile App
Learning to Surf: Lessons to Help Patients Recover from Major Cardiac Events
Examining the Harm Done by Sarah Palin’s “Death Panel” Rhetoric

Advaxis [ADXS], the 2012 winner of Best Therapeutic Vaccine in the VIE awards, is a development stage biotechnology company with the intent to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under exclusive license from the University of Pennsylvania that utilize live, attenuated Listeria monocytogenes bio-engineered to secrete antigen/adjuvant fusion proteins.

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3, locally advanced cervical cancer, recurrent/refractory cervical cancer (India), and head & neckcancer. Over 15 distinct constructs are in various stages of development, developed directly by the company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. The stock has fluctuated over the last 3 months, peaking at $0.14 in March just after Best Therapeutic Vaccine win before settling at around $0.10 in recent weeks.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma.

In mid-May, Biovest announced it will file for market approval in the European Union for BiovaxID®. EMA approval would establish BiovaxID as the first cancer vaccine available in Europe for lymphoma patients.

The stock peaked mid February at $0.75 after being covered in several media outlets including Drug Discovery New, OneMedResarch and Fox News website which predicted the advance of Cancer vaccines in 2012 including BiovaxID® Lymphoma Vaccine. It has since been slowly declining and has hovered in the $0.45 range in recent weeks.

Stay tuned for an in-depth look into the advantages and disadvantages of big pharma’s new immunotherapy toys, and why a certain failure in Europe may be an omen. We’ll look at how the disruptive technologies in our wheelhouse stack up to the companies that big pharma has committed to.

 

TAGGED:cancerpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Streamlining Healthcare Operations: How Our Consultants Drive Efficiency and Overall Improvement
Global Healthcare Policy & Law
June 11, 2025
magnesium supplements
The Wide-Ranging Benefits of Magnesium Supplements
Health
June 11, 2025
Preparing for the Next Pandemic: How Technology is Changing the Game
Technology
June 6, 2025
migraine home remedies and-devices
The Best Home Remedies for Migraines
Health Mental Health
June 5, 2025

You Might also Like

hearts in healthcare rehumanizing healthcare delivery
Specialties

Hearts in Healthcare – Rehumanizing the Healthcare System

July 2, 2012

FDA Asks Manufacturers of Hip Replacements To Study Failure Rates

May 11, 2011
SpecialtiesWellness

5 Critical Health Risks That Can Be Deadly For Seniors

September 20, 2018
SpecialtiesWellness

The Mirror Condition: Fibromyalgia and Getting the Right Diagnosis

February 15, 2018
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?